Skip to main content
. 2024 Apr 26;10:34. doi: 10.1038/s41523-024-00639-1

Fig. 1. Invasive disease-free survival by relative dose intensity subgroup in patients treated with abemaciclib.

Fig. 1

RDI was defined as the average daily dose of abemaciclib received by each patient over the treatment duration, relative to the full dose (150 mg twice per day). Among the 2791 abemaciclib-treated patients, 2783 had complete treatment exposure information for RDI calculation and thus were included in this analysis. *Estimated by the Kaplan-Meier method. For efficacy analyses, patients were divided into three equal-sized subgroups according to their abemaciclib RDI. Data cutoff date: July 01, 2022. CI confidence interval, IDFS invasive disease-free survival, RDI relative dose intensity.